JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB136083

Anti-ATPBD3 antibody

Be the first to review this product! Submit a review

|

(3 Publications)

Rabbit Polyclonal ATPBD3 antibody. Suitable for WB and reacts with Human samples. Cited in 3 publications. Immunogen corresponding to Synthetic Peptide within Human CTU1.

View Alternative Names

ATPBD3, NCS6, CTU1, Cytoplasmic tRNA 2-thiolation protein 1, ATP-binding domain-containing protein 3, Cancer-associated gene protein, Cytoplasmic tRNA adenylyltransferase 1

2 Images
Western blot - Anti-ATPBD3 antibody (AB136083)
  • WB

Unknown

Western blot - Anti-ATPBD3 antibody (AB136083)

All lanes:

Western blot - Anti-ATPBD3 antibody (ab136083) at 1/500 dilution

All lanes:

293 cell lysate at 30 µg

Predicted band size: 36 kDa

false

Western blot - Anti-ATPBD3 antibody (AB136083)
  • WB

CiteAb

Western blot - Anti-ATPBD3 antibody (AB136083)

ATPBD3 western blot using anti-ATPBD3 antibody ab136083. Publication image and figure legend from Trzaska, C., Amand, S., et al., 2020, Nat Commun, PubMed 32198346.

ab136083 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab136083 please see the product overview.

DAP interferes with the activity of FTSJ1.a Determination by tandem mass spectrometry of the amino acid incorporated at the PTC position. Firefly luciferase from HEK293FT cells transfected with the Fluc-int-UGA construct was immunoprecipitated and digested with trypsin. The MS/MS spectrum of the peptide containing the PTC position and the sequence determination are shown. The upper red and blue sequences indicate the amino acids validated, respectively, by detection of Nter and Cter peptide fragments (b and y ion series). Peptide fragments y6 and y7 clearly identify tryptophan (W) at the PTC position. The black peaks correspond to non-attributed mass-to-charge ratio (m/z) values. The green peaks are internal fragments that do not contain an extremity of the peptide. b The efficiency of UGA readthrough by DAP decreases with increasing amounts of FTSJ1 but not with increasing amounts of CTU1. Readthrough efficiency was determined by measuring luciferase activity in HeLa cells co-transfected with the firefly luciferase construct described in Fig. 1b and with increasing amounts of an expression vector for either FTSJ1 or CTU1 (0.5, 1, or 2 µg). The empty expression vector (E.v.) was used as control. The cells were then exposed to 0, 0.39, 0.78, 1.56, 6.25, 25, 100, 300, or 600 µM DAP for 24 h before measuring the luciferase activity. The experiment was performed twice and the results of both experiments (Exp1 and Exp2) are shown. c Western blot analysis of FTSJ1 and CTU1. d 2′-O-methylation analysis of tRNATrp, tRNASER, and tRNAGLN by RiboMethSeq. HeLa cells were incubated for 24 h with DMSO or with 25 µM DAP. A MethScore was attributed to each tRNA 2′-O-methylation in tRNA purified from HeLa cells treated with DAP (dark green histogram) or DMSO (light green histogram). The results of three independent experiments are indicated with the symbols square, point, or triangle. e Analysis of DAP affinity column eluates shows that DAP interacts with FTSJ1. HeLa-cell extract was incubated with DAP covalently bound to beads or with beads alone. Proteins bound to the columns were eluted with excess DAP and the eluates analyzed by western blot. A molecular weight marker is indicated to the left of each gel. p-values (p) were calculated using Student’s t-test. Source data are provided as a Source Data file.

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

Synthetic Peptide within Human CTU1. The exact immunogen used to generate this antibody is proprietary information.

Q7Z7A3

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/1000", "WB-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.88% Sodium chloride
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ATPBD3 also known as ATP-binding domain 3 functions as an enzyme involved in energy metabolism. It possesses ATPase activity which allows it to hydrolyze ATP the energy currency of the cell. With a molecular mass of approximately 60 kDa ATPBD3 plays a significant role in cellular energy management. This protein is widely expressed in numerous tissues indicating its importance in diverse cellular activities. Cells harness ATPBD3's energy-converting abilities to sustain various metabolic processes critical for cell viability and function.
Biological function summary

ATPBD3 facilitates energy homeostasis and cellular metabolic processes. It performs as part of a complex that coordinates multiple cellular activities ensuring efficient energy production and utilization. This precise management of cellular energy resources is important for supporting cell survival promoting cell growth and regulating apoptosis. Through these activities ATPBD3 contributes significantly to maintaining cellular homeostasis and responding to metabolic demands.

Pathways

ATPBD3 integrates into cellular energy metabolism and stress response pathways. It engages in ATP synthesis and hydrolysis processes critical for energy production and cellular adaptation. The protein functions alongside other metabolic enzymes like AMP-activated protein kinase (AMPK) which senses cellular energy status and regulates metabolic pathways. ATPBD3's role in these pathways showcases its involvement in cellular responses to energy fluctuations aiding cells in adapting to metabolic shifts.

Faulty regulation or expression of ATPBD3 associates with metabolic disorders such as obesity and type 2 diabetes. Abnormalities in ATPBD3 function can disrupt energy balance leading to metabolic imbalances linked to these conditions. Additionally ATPBD3 interactions with proteins such as AMPK highlight its potential influence on glucose metabolism and insulin signaling pathways which are dysregulated in metabolic diseases. Investigating ATPBD3's role and interactions may offer insights into novel therapeutic strategies for addressing these metabolic challenges.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Plays a central role in 2-thiolation of mcm(5)S(2)U at tRNA wobble positions of tRNA(Lys), tRNA(Glu) and tRNA(Gln). Directly binds tRNAs and probably acts by catalyzing adenylation of tRNAs, an intermediate required for 2-thiolation. It is unclear whether it acts as a sulfurtransferase that transfers sulfur from thiocarboxylated URM1 onto the uridine of tRNAs at wobble position.
See full target information CTU1

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 11:1509 PubMed32198346

2020

2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations.

Applications

Unspecified application

Species

Unspecified reactive species

Carole Trzaska,Séverine Amand,Christine Bailly,Catherine Leroy,Virginie Marchand,Evelyne Duvernois-Berthet,Jean-Michel Saliou,Hana Benhabiles,Elisabeth Werkmeister,Thierry Chassat,Romain Guilbert,David Hannebique,Anthony Mouray,Marie-Christine Copin,Pierre-Arthur Moreau,Eric Adriaenssens,Andreas Kulozik,Eric Westhof,David Tulasne,Yuri Motorin,Sylvie Rebuffat,Fabrice Lejeune

Nature communications 10:5492 PubMed31792210

2019

Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Sunwang Xu,Ming Zhan,Cen Jiang,Min He,Linhua Yang,Hui Shen,Shuai Huang,Xince Huang,Ruirong Lin,Yongheng Shi,Qiang Liu,Wei Chen,Man Mohan,Jian Wang

Nature communications 9:3925 PubMed30254264

2018

An OB-fold complex controls the repair pathways for DNA double-strand breaks.

Applications

Unspecified application

Species

Unspecified reactive species

Shengxian Gao,Sumin Feng,Shaokai Ning,Jingyan Liu,Huayu Zhao,Yixi Xu,Jinfeng Shang,Kejiao Li,Qing Li,Rong Guo,Dongyi Xu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com